RELATIONSHIP BETWEEN SIX MINUTE WALK TEST, SPIROMETRY AND COPD ASSESSMENT TEST (CAT) SCORES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS

Dissertation submitted In Partial Fulfilment of the

Requirements for the Degree of

DOCTOR OF MEDICINE

TUBERCULOSIS & RESPIRATORY MEDICINE

Branch - XVII

2014-2017

DEPARTMENT OF TUBERCULOSIS & RESPIRATORY MEDICINE

Government Stanley Medical College & Hospital

Chennai-600 001

THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY

CHENNAI-600 032

April 2017

CERTIFICATE

This is to certify that the dissertation on " **Relationship between Six minute walk test, Spirometry and COPD Assessment Test (CAT) Scores in chronic obstructive pulmonary disease patients**" is a record of research work done by **Dr.P.ANAND** in partial fulfilment for M.D. (TUBERCULOSIS & RESPIRATORY MEDICINE) Examination of the Tamil Nadu Dr. M. G .R. Medical University to be held in April 2017.The period of study is from October 2015 to July 2016.

Dr. R. SRIDHAR M.D, DTRD.,

Professor & Head of the Department,

Department of Tuberculosis

& Respiratory Medicine,

Stanley Medical College,

Chennai- 600 001.

Dr. ISAAC CHRISTIAN MOSES

M. D, FICP,FACP.,

Dean,

Stanley Medical College,

Chennai- 600 001.

CERTIFICATE BY GUIDE

This is to certify that the dissertation on"**Relationship between Six minute walk test, Spirometry and COPD Assessment Test (CAT) Scores in chronic obstructive pulmonary disease patients**" is a record of research work done by **Dr.P.ANAND** in partial fulfilment for M.D. (TUBERCULOSIS & RESPIRATORY MEDICINE) Examination of the Tamil Nadu, Dr. M. G .R. Medical University to be held in April 2017.The period of study is from October 2015 to July 2016.

DR.R.SRIDHAR, M.D, DTRD.,
Professor & Head of the Department,
Department of Tuberculosis &
Respiratory Medicine,
Stanley Medical College & Hospital,
Chennai- 600 001.

DECLARATION

I hereby declare that the dissertation entitled "**Relationship between Six minute walk test, Spirometry and COPD Assessment Test (CAT) Scores in chronic obstructive pulmonary disease patients**" submitted for the Degree of Doctor of Medicine in M.D., Degree Examination, Branch XVII, TUBERCULOSIS & RESPIRATORY MEDICINE is my original work and the dissertation has not formed the basis for the award of any degree, diploma, associate ship, fellowship or similar other titles. It had not been submitted to any other university or Institution for the award of any degree or diploma.

Place: Chennai — Signature of the Scholar

Date: 26.09.16 — (Dr.P.ANAND**)**

ACKNOWLEDGEMENT

Language with all elaborations seems to be having limitation especially when it comes to expression of feelings. It is incapable of conveying in words all the emotions and feelings one wants to say.

It would take pages to acknowledge everyone who, in one way or another has provided me with assistance, but certain individuals deserve citation for their invaluable help.

I would like to express my heartfelt thanks to **Dr. ISAAC CHRISTIAN MOSES M.D, FICP, FACP.,** Dean, Stanley Medical College and Hospital for giving me permission to conduct this study.

I find words insufficient to express my deep sense of gratitude for my esteemed and reverend teacher, my chief **Prof.Dr.R.SRIDHAR, M.D, D.T.R.D,** Head of the Department, Dept. of Tuberculosis & Respiratory Medicine, Stanley Medical College and Superintendent, Govt. Hospital of Thoracic Medicine, Tambaram Sanatorium, for his ever-inspiring guidance and personal supervision.

The finest privilege in my professional career has been the opportunity to work under his inspirational guidance.

I thank Associate professor **Dr.V.VINOD KUMAR M.D,(CHEST), DNB.** for his constant encouragement and guidance throughout my postgraduate course.

I would like to express my sincere thanks and heartful gratitude to Associate professor **DR.D.NANCY GLORY M.D.,** for her constant support, enthusiasm and valuable guidance throughout my work.

Words fall short in expressing my sincere gratitude for other eminent teachers in our department, who helped me in my work **Dr.S.Kumar M.D, Dr.G.Allwyn Vijay M.D, Dr. S.P.Vengadakrishnaraj D.T.C.D,DNB, Dr.K.Maheswaran M.D.**

I express my sincere thanks to all the assistants in our department for their support. I heartfully thank my senior **Dr.S.Navaneetha Krishnan,M.D** and junior colleagues for their enthusiasm and involvement for completing this study.

I have no words to express my sincere and heartfelt gratitude to my father **Mr**.**A.PUGAZHENDHI** and my mother **Mrs.B.KANCHANA** who always supported me throughout my life as a student, guided me to solve my problems and helped me to face all kind of difficulties. Their love, affection and support enabled me to reach this stage of life. This work is dedicated to my beloved father who dedicated his entire life for wellbeing of me and my family..

I will always be grateful to my dear wife **Dr.K.ANUJA** for being cooperative, for sharing my enthusiasm and dismay and constantly supporting my ambitions and struggle. This work would not have been possible without her support in my difficult times.

Last but definitely not the least, I would like to thank all the patients who cooperated with me throughout my work.

Finally it is endowment of spiritualism and remembrance of almighty for all that I achieved.

CONTENTS

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) comprises of two diseases namely chronic bronchitis and emphysema. Chronic bronchitis is defined as "daily productive cough for at least three consecutive months for more than two successive years"[1]. In 1962, American Thoracic Society (ATS) defined emphysema as an "anatomic alteration of the lung characterized by an abnormal enlargement of the air spaces distal to the terminal, non-respiratory bronchiole, accompanied by destructive changes of the alveolar walls"[2]. In 1984 , the National Heart, Lung and Blood Institute defined emphysema as "a condition of the lung characterized by abnormal, permanent enlargement of airspaces distal to the terminal bronchiole, accompanied by the destruction of their walls, and without obvious fibrosis"[3]. McDonough *et al*[4] have reported that "the permanent enlargement of the distal airspaces may serve only as a structural biomarker, being a secondary result of small airway inflammation and destruction"[5]. This shows that in COPD, not only airway abnormality is present but also airspace abnormality is present.

PREVALENCE:

In COPD,prevalence rates vary considerably depending on the methods used for the diagnosis and classification. In studies where spirometry is used to diagnose COPD, the prevalence rates are higher than the prevalence rate from studies where questionnaires are used.[6]

COPD usually occurs after the age of 40 years. Incidence of COPD increases with an increase in age. The following chart shows that as the age advances, the prevalence rate also increases.



Fig.1: Prevalence of COPD in different age groups.

The global prevalence of COPD is approximately 9-10 per cent[7].

According to INSEARCH study , in India, COPD prevalence among men is 9.02 million and among women is 5.75 million.[8]

The following table shows various studies done in India regarding prevalence of COPD.

Table 1: COPD Prevalence studies done in India.

Study by	**Population**	**COPD prevalence**	
		male	**Female**
Wig et al (1964)	Rural Delhi	3.36%	2.54%
Viswanathan (1966)	Patna	2.12%	1.33%
Radha et al (1977)	New Delhi	8.1%	4.6%
Thiruvengadam et al (1977)	Madras(Now Chennai)	1.9%	1.2%
Jindal (1993)	North India-Urban Rural	4.2% 6.2%	1.6% 3.9%
Ray et al (1995)	South India	4.08%	2.55%
INSEARCH	12 districts across India	4.46%	2.86%

In all these studies, questionnaires were used to find out the prevalence of COPD. This underestimates the true spirometry based prevalence of COPD.

A COPD prevalence study conducted in Pune by using post bronchodilator Spirometry and questionnaire, reported nearly 2-fold higher prevalence compared to INSEARCH study.[9]

Another collaborative study conducted in rural Kashmir with subjects aged more than 40 years by applying BOLD protocol, concluded that the prevalence of Stage1 or higher COPD was 19.3%[10]. Studies with prevalence data based on spirometry is very few in India. To overcome this, WHO-Govt. of India committee group has approved the use of 6MWT, PEFR and questionnaire based analysis for assessment of severity in COPD[11].

Reason for interest in this topic:

People with COPD are affected socially and economically. So it is necessary to diagnose COPD early and assess the disease severity and treat it appropriately.

In COPD,the disease severity is usually assessed by the post-bronchodilator FEV_1 done by using spirometry. But spirometry has its own disadvantages. It is effort dependent and many times it may not give the correct reading, if the patient does not blow properly. Patients require a little extra effort to do the test. They generally do not understand the science behind it. Spirometry test is also costly.It is beyond the reach of patients who are economically backward and who are treated by primary care physicians.

6MWT is a simple and practical test. Patients are made to walk for 6 minutes and the distance covered by the patients after 6 minutes is measured. It is used for pre and post operative evaluation in lung transplantation and lung volume reduction surgeries. It is also used for assessing the prognosis and response to treatment in various respiratory diseases. American thoracic society approved this test in 2002, as a standard test for clinical pulmonary function laboratories. Also CAT score is a simple questionnaire available in local languages to assess the impact of COPD.

Therefore in this study we aim to find out correlation of Six Minutes Walk Test and CAT score with Spirometric and Clinical parameters in COPD patients. Also we tried to find out whether 6 MWT and CAT score can be used to assess the severity of the disease in COPD patients.

REVIEW OF LITERATURE

DEFINITION OF COPD

"COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients."[12]

RISK FACTORS FOR COPD:

Table 2: Risk factors for COPD

Environmental	**Host based**
Smoking	Genetic factors
Occupational exposure	Airway hyper reactivity
Air pollution	
Childhood respiratory infection	
Low socioeconomic status	

Smoking:

Tobacco smoking is the most common risk factor for developing COPD[13]. A Swedish cohort study [14] and Denmark study [15] reported that population attributable risk for development of COPD in smokers respectively as 76.2% and 74.6%. In India most of them are using bidi for smoking than cigarette[16]. Ventilatory function deterioration is common among smokers than non-smokers. .

In males average decline in FEV_1 is approximately around 9 ml per year for each pack-year of smoking. In females average decline in FEV_1 is approximately around 6 ml per year for each pack-year of smoking.

Though tobacco content is low in bidi, bidi smokers are more vulnerable to develop COPD than cigarette smokers.

Risk of COPD is directly proportional to the number of cigarettes or bidis smoked per day.Risk also increases with increase in duration of smoking. The risks are lower at a lower dose and lesser duration of smoking [17].The Lung Health Study [18] found that there is an accelerated decline in FEV_1 in COPD patients if they continue smoking.

Environmental Tobacco Smoke:

ETS exposure is an important risk factor for developing COPD among nonsmokers especially women and children.

Occupational Exposure:

Chronic inhalation of particles and gases carry a greater risk for COPD. But we are not able to estimate the correct prevalence of COPD among workers because most of the workers are smokers and those with COPD drop out from work. The American Thoracic Society states that 15% of COPD cases are due to occupational exposure.

People working in rubber industry,plastic industry,leather industry are at increased risk of COPD.[19] Also, people who work in textile mills and food product manufacturing are also at increased risk.

Outdoor Air Pollution:

In developing countries like India, especially in urban population, outdoor air pollution has been implicated as a cause for COPD and various other respiratory diseases.[20] It is due to pollutants from industries and motor vehicles causing pathological changes in lung and airway. A previous study observed that higher traffic density is associated with increased risk of COPD in women. These pollutants may cause bronchial hyperactivity, airway oxidative stress, pulmonary and systemic inflammation[21].

Indoor Air Pollution:

Biomass fuel is obtained from the combustion of dried dung, wood, and crop residue. Exposure to biomass fuel is an important source of indoor air pollution. It is an important cause of COPD among women especially in rural India. Combustion of biomass fuel in closed spaces results in the inhalation of the toxic gases which contributes to the development of COPD. The risk of COPD among women in urban areas is less when compared to women in rural areas. This is because women in rural areas use biomass fuel whereas women in urban areas use LPG as fuel for cooking purposes.

Alfa-1 Antitrypsin Deficiency:

It accounts for around 1-2% of total cases of COPD.

Conditions suggesting alpha 1 anti-trypsin deficiency:

1. Early onset emphysema (age less than 45 years).
2. Emphysema in a non-smoker.
3. Emphysema predominantly in lung bases.
4. Family history of early onset emphysema or non-smoking related emphysema.
5. Bronchiectasis without any other aetiology.

Childhood Lower Respiratory Tract Infections:

Ventilatory function in adults depends on the lung function in their childhood days. Hence Lower respiratory tract infections during childhood that affect lung development, tend to increase the risk of developing COPD later in life. [22].

Genetic Factors:

Polymorphisms of genes involved in protease- antiprotease balance, antioxidant function, inflammation, and immune responses have been implicated in COPD.

In one study, a combination of both candidate gene and positional cloning approaches were used. Boston Early-Onset COPD study evaluated a single nucleotide polymorphism (SNPs) in and around the transforming growth factor-β1 (TGF-β1) region located in chromosome 19q and found that it was linked to pre-bronchodilator FEV1in smokers. This study was later confirmed by National Emphysema Treatment Trial (NETT), which includes not only the initial phenotype of low pre-bronchodilator FEV1, but also the presence of radio graphically confirmed emphysema.

Airway Hyperresposiveness:

In COPD, airway hyper-responsiveness is associated with accelerated decline in FEV1.However airway hyper-responsiveness does not predict bronchodilator responsiveness.

Other Miscellaneous Factors:

Low socioeconomic status, advancing age are some of the factors associated with increased risk of COPD. This is because, an increased amount of smoking is seen in people with low socioeconomic status. Also, old age people receive deficient medical care.

PATHOGENESIS:

a) Inflammation:

Inflammation of the lower respiratory tract plays an important role in pathogenesis of COPD. Following the exposure to tobacco smoke and other inhaled particles, there is an recruitment of inflammatory cells in the lungs and airways. These inflammatory cells are neutrophils, eosinophils, macrophages and lymphocytes. They cause lung injury and disrupt the normal mechanism of lung repair. Bronchoalveolar lavage (BAL) fluid collected from smokers contain more macrophages when compared to non smokers.



Fig.2 : Basic view of COPD pathology



Fig. 3 : Overview of Pathogenesis in COPD.

b) Proteinase and Antiprotease Imbalance:

In COPD , there is an imbalance in the production of proteinase and antiproteinase.Major proteinase that affect lung parenchyma are neutrophil elastase, Proteinase 3, cathepsin B, cathepsin L, cathepsin S, MMP (Matrix Metalloproteinase).Some of the antiproteinases are alfa 1 antitrypsin, Matrixmetalloproteinase inhibitors, alfa 2 macroglobulin, Secretory leukocyte protease inhibitor(SLPI), Elafin and cystatin C. Neutrophil elastase causes parenchymal destruction, mucous gland hyperplasia and induces mucus secretion.

c) Oxidative Stress

Cigarette smoke contains many chemicals that are highly reactive oxidant species.Also, the inflammation itself generates oxygen-free radicals leading to tissue damage. In vitro study done by Schaberg et al showed that airway neutrophils and alveolar macrophages generate more oxygen free radicals such as hydrogen peroxide, hydroxyl radicals, and superoxide radicals in smokers than non-smokers.

Oxidative stress causes the damage of extracellular matrix and inactivation of key anti-oxidant defences . Antioxidants give protection against oxidative injury. Superoxide dismutase, Catalase, and glutathione peroxidase are some of the antioxidants that give protection against oxidation injury. Copper and zinc dependent superoxide dismutase are found in cytoplasm whereas manganese dependent superoxide dismutase is found in mitochondria. Vitamin A and Vitamin E are present in epithelial lining fluid. They also act as antioxidants.

Elastase-Antielastase Hypothesis:

Lung Elastic Fiber

Destruction of lung elastic fibres plays a key role in the development of emphysema. Extracellular matrix of lung parenchyma is organized as 1.axial system 2.parenchymal system 3.peripheral system.

Axial system extends from central airway to alveolar ducts. Parenchymal system is formed by matrix of alveolar septae. Peripheral system arises from visceral pleura and extends into alveolar septae. Distal to respiratory bronchiole, axial system forms helix encircling alveolar duct. Elastin is the main component of axial system and these elastic fibres provide elastic recoil throughout respiratory cycle. Elastin is resistant to many proteinases, however many enzymes are capable of degrading elastin such as neutrophils elastase, proteinases 3, cathepsin G, MMP-9, MMP-12, cathepsin L and cathepsin S.

Lung collagen turnover:

Alveolar wall collagen degradation and abnormal collagen deposition in alveolar wall are involved in pathogenesis[23]. In emphysematous lung the number of pores of kohn is high and the pores are larger than the normal ones. Because of interstitial lung collagenous degradation, there is an enlargement of the pores of kohn.

PATHOPHYSIOLOGY:

The following physiological abnormalities occur in COPD:

- mucous hypersecretion and cilliary dysfunction,
- airflow limitation and hyperinflation,
- gas exchange abnormalities,
- pulmonary hypertension.

Mucous Hypersecretion and Cilliary Dysfunction

Mucus is secreted from submucosal glands and airway goblet cells. There is a hyperplasia of goblet cells and hypertrophy of submucosal glands in COPD. Also there is an increase in ratio of glandular mucus cells to serous cells.This increased mucus secretion is due to hypersecretion of MUC5B proteins than typical MUC5AC forms.There is also an increase in MUC2 form.

Airflow Limitation And Hyperinflation

Expiratory airflow limitation is the hallmark of COPD. It is irreversible. The smaller conducting airways <2 mm in diameter is the major site of the airflow limitation. Airway remodelling (fibrosis and narrowing) occur in these airways.



Fig.4: Changes at alveolar level in COPD

Gas Exchange Abnormalities

The various anatomical abnormalities lead to ventilation perfusion mismatch resulting in abnormal gas exchange. It results in arterial hypoxaemia with or without hypercapnia.It also causes abnormal DLCO.

Pulmonary Hypertension

Late in the course of COPD, gas exchange abnormalities become severe, leading to pulmonary hypertension.



Fig. 5 : Pathogenesis of Pulmonary hypertension in COPD.

MANIFESTATIONS OF COPD:

EMPHYSEMA:



Fig.6: Types of Emphysema

Centrilobular Emphysema

In centrilobular emphysema, pores of kohn is the initial site of destruction. The respiratory bronchioles appears dilated and enlarged.The alveolar duct and alveoli appears normal. Centrilobular emphysema commonly affects upper zone. Most affected segments are apical & posterior segments of upper lobe . In severe cases, the destruction may proceed towards the periphery of the lobule, so that distinction between centrilobular and paraseptal emphysema becomes blurred.

Panlobular Emphysema

Lower lobe is affected predominantly in panlobar emphysema. Alveolar duct and alveoli distinction is lost. The sharp angles of alveoli are also lost. The pores of Kohn are more uniform and inconspicuous when compared to centrilobular emphysema. Mild panlobular emphysema is difficult to diagnose. Pan lobular emphysema is most commonly seen in patients with $alpha_1$ antitrypsin deficiency, constrictive bronchiolitis, and obliterative bronchiolitis.

Paraseptal Emphysema

More distal part of the acinus is affected like alveoli and alveolar duct. It is commonly seen adjacent to the pleura**,** along lobular septa and at the margins of lobules and acini.

Irregular Emphysema:

Irregular emphysema is adjacent to a scar, so it is otherwise called as paracicatricial emphysema. Most scars within lungs are small, so emphysema is limited in extent.

CHRONIC BRONCHITIS:

It is characterized by chronic cough and sputum production.Chronic mucus hypersecretion associated with airflow obstruction is called chronic obstructive bronchitis.

SMALL AIRWAY DISEASE:

The smaller conducting airways (< 2 mm in diameter) is a major site of airway obstruction in COPD [24]. Inflammation, fibrosis, luminal plugs occur in small airway leading to increased airway resistance.

CLINICAL FEATURES:

Dyspnoea is seldom a compliant until FEV1 falls below 60% of predicted. Assessment of dyspnea is done by MMRC dyspnoea scale.

Table 3: MMRC dyspnoea scale

The Modified Medical Research Council (MMRC) Dyspnoea Scale

Grade of dyspnoea	Description
0	Not troubled by breathlessness except on strenuous exercise
1	Shortness of breath when hurrying on the level *or* walking up a slight hill
2	Walks slower than people of the same age on the level because of breathlessness *or* has to stop for breath when walking at own pace on the level
3	Stops for breath after walking about 100 m *or* after a few minutes on the level
4	Too breathless to leave the house *or* breathless when dressing or undressing

The other symptoms are cough with expectoration and fever if there is acute exacerbation. Unable to do normal day to day activities, sleep disturbances during night are the other symptoms seen in COPD patients in moderate to severe patients.

Hyperinflation is common in moderate and severe COPD, it produces increase in residual volume and also increased ratio between residual volumes to total lung capacity. Hyperinflation may be beneficial in COPD by increasing lung volume, elastic recoil pressure, and also decreasing airway resistance there by preserving maximum expiratory airflow.

Hyperinflation causes increase in dyspnoea by:

1. Decreased apposition between the muscles of abdomen and the diaphragmatic muscle.
2. Flattening of diaphragm causes increased radius of curvature, thereby decrease in transpulmonary pressure.
3. Shorter diaphragm muscle fiber length causes decrease in the force of contraction.

   During exercise, hyperinflation worsens because of airflow obstruction during expiration. HIV/AIDS is also associated with premature emphysema.

Lung volume measured by helium dilution method and nitrogen washout plethysmography shows elevated total lung capacity and residual capacity. The carbon monoxide diffusion capacity is decreased in patients who have an FEV1 less than 1.0 L

Signs:

Inspection[25]

Pursed-lip breathing

Barrel shaped chest

Filling of neck veins during expiration

Hoover sign

Short trachea

Pulsus paradoxus

Increased anteroposterior diameter of the chest (barrel-shaped chest)

Reduced chest movements

Peripheral edema

Muscle Wasting

Palpation: Reduction in the expansion of the chest.

Percussion: Tympanic note heard due to hyperinflation of the lung.

Auscultation: Decrease in respiratory sounds and expiration is prolonged, polyphonic wheeze during expiration.

Chest X Ray finding:



Fig.7: Chest Xray PA view in COPD

1. Increased radiolucency.
2. Bilateral hyperinflation.
3. Decreased peripheral blood vessel shadows.
4. Flattening of diaphragm.
5. Decreased cardio-thoracic ratio- cardiac diameter less than 11.5cm with vertical heart and lung seen below the heart.
6. Increased intercostal space.



Fig.8: Chest Xray lateral view in COPD

1. Increase in retro cardiac space.
2. Increased in retrosternal area- measurement taken between anterior aspect of ascending aorta and the posterior aspect of sternum 3 cm below manubriosternal joint.
3. Obtuse costophrenic angle.

HRCT lung:

Centrilobular Emphysema: In this type there is an ill-defined margin with areas of low attenuation area. In early stage of COPD, upper zone of lung is usually affected with low attenuated areas closely related to centrilobular arteries. Lung surrounding the low attenuated area appears normal.

Panacinar Emphysema: Lung destruction is uniform and gives rise to generalize low attenuation density of lung. Panacinar emphysema affects the lower lobe predominantly.

Paraseptal Emphysema: Sub pleural well-marginated low attenuation area with distinct hairline walls are seen. This pattern resembles saw teeth appearance.

Emphysema can be assessed by using lung density index. Gevenios et al study among COPD patients showed density of -950 HU providing an accurate estimation of COPD.



Fig.9: HRCT picture in a upper lobe emphysema

Goddard classification of COPD [26]

1 point: scattered emphysematous lesion 1 cm or less in diameter.

2 point: large size Low Attenuation Area (LAA) due to the fusion of emphysematous lesions.

3 point: LAA occupies an even larger area by the more pronounced fusion.

4 point: most of the lung occupied by emphysema and only a small area of normal lung.

Visual evaluation of pulmonary emphysema [27]

Right and left lung are divided into six areas namely upper, middle, and lower lung fields on both sides. Degree of severity of pulmonary emphysema is graded based on five-point scale

0 point: no emphysematous lesions.

1 point: occupies less than 25 % of the entire lung field.

2 point: occupying from 25% to less than 50% of the entire lung field.

3 point: occupying from 50% to less than 75% of the entire lung field.

4 point: occupying more than 75 % of the entire lung field.

Maximum total = 24 points.

Spirometric assessment:

Spirometry is essential for diagnosis of COPD. It is also useful for classification of severity and assessing the progression of the disease. For the diagnosis, post bronchodilator FEV1/FVC should be less than 0.70. The severity of the disease is based on the FEV1.

Table 4: Classification Of Severity Of Airflow Limitation In COPD.

Category/Severity Stage	FEV_1/FEV	FEV_1 (% Predicted)
Normal (healthy patients)	0.80	~100
I: Mild	<0.70	≥80
II: Moderate	<0.70	50 to <80
III: Severe	<0.70	30 to <50
IV: Very Severe	<0.70	<30[a]

DLCO:

It is decreased in patients with emphysema. This is because,the area of alveolar capillary membrane is greatly reduced.

BODE index:

Body mass index, **O**bstructive ventilatory defect severity, **D**yspnoea severity, and **E**xercise capacity.[28]

Table 5: Calculation of BODE index

VARIABLE	POINTS ON THE BODE INDEX			
	0	1	2	3
FEV1(% predicted)	≥65	50-64	36-49	≤35
Distance walked in 6 min(in meters)	≥350	250-349	150-249	≤149
MMRC dyspnoea scale	0-1	2	3	4
Body mass index	>21	≤21		

2 year mortality in patients with BODE score greater than 7 is 30%; If the score is 5 to 6,there is 15% mortality risk. If the score is less than 5, there is risk of 10% mortality in 2 year period.

COMBINED ASSESSMENT OF COPD:

Inorder to improve the management of COPD, combined assessment is done. Here the patients are placed under four categories A,B,C,D based on GOLD staging, mMRC grading, CAT scoring and exacerbation risk.



Fig.10: Combined assessment of COPD.

Table 6: Combined assessment of COPD.

Combined assessment of COPD

PATIENT	CHARECTERSTIC	SPIROMETRIC CLASSIFICATION	EXACERBATION PER YEAR	CAT	mMRC
A	Low Risk Less Symptoms	GOLD 1-2	≤ 1	< 10	0-1
B	Low Risk More Symptoms	GOLD 1-2	≤ 1	≥ 10	≥ 2
C	High Risk Less Symptoms	GOLD 3-4	≥ 2	< 10	0-1
D	High Risk More Symptoms	GOLD 3-4	≥ 2	≥ 10	≥ 2

Differential Diagnosis:

- Bronchial asthma
- Bronchiectasis
- Follicular bronchiolitis
- Obliterative bronchiolitis
- Diffuse panbronchiolitis
- Constrictive bronchiolitis
- Proliferative bronchiolitis

COMORBIDITIES ASSOCIATED WITH COPD PATIENTS:

Because of common risk factors, COPD patients will have more number of comorbidities like cardiovascular disease, atherosclerosis, hypertension, depression, pulmonary embolism and lung cancer. Comorbidity occurrence is independent of severity of airflow limitation which can occur at any stage of the disease.



Fig.11: Systemic manifestations of COPD.

THERAPEUTIC OPTIONS AVAILABLE:

Smoking Cessation:

Since Smoking is a major risk factor for the development of COPD, cessation of smoking is the main aim to prevent COPD . Health care professional should provide information regarding smoking cessation messages.

Behavioural approaches:

The clinicians can use the following method while counselling the patients on.

Popularly referred as “the five A’s”---

ASK (about tobacco use)

ASSESS (the status and severity of use)

ADVICE (to stop)

ASSIST (in smoking cessation)

ARRANGE (follow-up program)

Group counselling:

These programs include lectures on pathophysiology of smoking, ill effects of smoking, consequences of smoking habit, group interactions and exercises. Success rate is in the range of 15-35% at the end of 1 year. These programs are run by several commercial and voluntary health organizations.

Gradual reduction VS Abrupt Abstinence:

In gradual reduction phase patients experience tobacco withdrawal symptom when their nicotine level falls below critical threshold level. They may also experience prolonged discomfort. So many people gradually return to their previous cigarette smoking level.

In Abrupt abstinence also, patients experience tobacco withdrawal symptoms. But craving for cigarette is less than gradual taperers. Also, the relapse rate is less.

Pharmacotherapy for Smoking Cessation

- Three classes of agents approved
  - Nicotine replacement
  - Bupropion
  - Varenicline
- Secondary agents(off label agents) used
  - Clonidine
  - Nortriptyline

Nicotine replacement therapies:

- Five nicotine replacement therapies approved
- Available as OTC (over the counter)

  - Lozenges
  - Gum(polacrilex)
  - Transdermal patches
- Available with a prescription
  - Nasal spray
  - Nicotine inhaler
- Others
  - Toothpicks and e cigarettes

Bupropion:

- Doubles quit rate when compared to placebo.
- Subjects with depression respond better to Bupropion than NRT.
- Combination of Bupropion + NRT superior to either alone.
- Dose 150 mgs daily for 3 days, then twice daily generally for 12 weeks.
- Side effect-Possible association with suicidal tendency.

Varenicline:

- It is a partial agonist of the α4β2 nicotinic receptor. It partially activates the receptor thereby mitigates withdrawal symptoms. It also prevents nicotine from acting and thus can reduce the rewarding & reinforcement effects associated with nicotine.
- Given orally - 0.5 mgs once daily for three days followed by 0.5 mgs twice daily for 4 days and then 1 mg twice daily for three months .

THERAPEUTIC OPTIONS:

The Pharmacological class of drugs that are available for the treatment of COPD are given below.

Table 7: COPD Medications

Beta$_2$-agonists
Short-acting beta$_2$-agonists
Long-acting beta$_2$-agonists
Anticholinergics
Short-acting anticholinergics
Long-acting anticholinergics
Combination short-acting beta$_2$-agonists + anticholinergic in one inhaler Combination long-acting beta$_2$-agonist + anticholinergic in one inhaler
Methylxanthines
Inhaled corticosteroids
Combination long-acting beta$_2$-agonists + corticosteroids in one inhaler
Systemic corticosteroids
Phosphodiesterase-4 inhibitors

Bronchodilators:

Bronchodilators will improve the FEV_1 by modifying tone of the airway smooth muscles.It widens the airway and thereby increases the expiratory flow .It also reduces dynamic hyperinflation during exercise and rest. Toxicity is dose related. Inhaler therapy is preferred, in which long acting bronchodilator is more efficacious than short acting drugs. Bronchodilators play central role in symptomatic management in COPD patients. Combination of different classes of bronchodilator drugs will improve efficacy and decrease the adverse effects.

Anti-cholinergic drugs:

Most commonly used drugs are ipratropium, oxitropium, Tiotropium. These drugs block the acetylcholine and act on muscarnic receptors. Short acting drugs block M_2, M3 receptors and pre-ganglionic junctional transmission is modified. Long acting drugs block M_3 and M_1 receptors. Anti-cholinergic drugs act longer duration than $beta_2$ agonists. Those with short action have 8 hours of bronchodilator activity and long acting has 12 hours of action[29]

$Beta_2$ agonist:

$Beta_2$agonist causes relaxation of smooth muscle present in the airway mediated via beta2 receptors, causing increased cAMP. Short acting bronchodilators usually have 4 to 6 hours of action, long acting drugs have action of 12 or more hours. To improve the compliance of treatment long acting drugs are used once daily in the treatment of COPD. Study conducted by Gregory Feldman [30] shows 150 micro gram of once daily indacaterol is more compliant for

the patients as well as less number of drop out. The only long acting beta agonist which has 24 hours of action is Indacaterol.

SABA- (Short Acting Beta Agonist)-e.g- Salbutamol.

LABA- (Long Acting Beta Agonist)- e.g-Salmetrol, formetrol & indacaterol.

A study was done done by James et al in COPD patients for comparison of Tiotropium and Indacaterol on trough FEV_1 after 12 weeks of treatment. It also evaluated safety and efficacy after 26 weeks of treatment.

They conclude that indacaterol more efficacious in bronchodilatation and has higher compliance than Tiotropium and placebo.

Adverse effects:

1. Sinus tachycardia, and precipitate cardiac disturbance in some patients.
2. Exaggerated somatic tremor.
3. Hypokalemia.
4. Tachyphylaxis.

Methylxanthines:

Xanthines act as non-selective phosphodiesterase inhibitors. Theophylline produces bronchodilation by blocking adenosine action. It improves the diaphragmatic muscle contraction, prevents respiratory muscle fatigue, increases ventilatory drive and potentiates catecholamine function.

Theophylline decreases cough by augmenting mucociliary clearance, reduces the late-phase antigen responses, suppresses leukocyte activation, and inhibits of mast cell histamine release.

Corticosteroids:

The role of Corticosteroids in reduction of pulmonary and systemic inflammation is controversial, so use of corticosteroid alone in management of stable COPD is not advised. But some study demonstrates that regular use of corticosteroid will produce improvement in lung function, reducing the frequency of exacerbation, improving symptom and quality of life especially in patients with more severe disease.

Adverse effects:

Commonly encountered adverse effects of corticosteroids are oral candidiasis, hoarseness of voice and skin bruising, Long term treatment is associated with pneumonia, osteopenia, and osteoporosis

Phosphodiesterase IV inhibitors:

Roflumilast is a phospodiesterase-4 inhibitor. It reduces exacerbations in patients with severe and very severe COPD and also in patients with chronic bronchitis.

Other Pharmacological Treatments:

Vaccines:

Vaccines are found useful in preventing exacerbations in COPD patients. Pneumococcal polysaccharide vaccine and influenza vaccine are the two vaccines commonly used in COPD patients.. Influenza vaccines can reduce serious illness. Killed influenza vaccine is preferred over the live influenza vaccine.

Antibiotics:

The use of antibiotics is currently indicated only in cases of bacterial exacerbations.

Alpha-1 antitrypsin therapy:

Replacement with alfa-1 antitrypsin is considered in patients with severe deficiency.

Pulmonary Rehabilitation:

Pulmonary rehabilitation is defined as "an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities. Integrated into the individualized treatment of the patient, pulmonary rehabilitation is designed to reduce symptoms, optimize functional status, increase participation, and reduce healthcare costs through stabilizing or reversing systemic manifestations of the disease".[31]

The first step is a screening interview. Patients medical history is completely reviewed and psychosocial problems are identified. Data including pulmonary function test, exercise tests, arterial blood gas analysis, chest xray, electrocardiogram are reviewed. Program content include education regarding disease, chest physiotherapy and breathing exercises. Specific goals are set that should be compatible with the patients needs and expectations. Support from the family members is also very important.

Long term oxygen therapy:

Supplemental oxygen is recommended in the following patients.

- PaO_2 of < 55 mmHg (or pulse oxygen saturation of < 88%), or
- PaO_2 56-60 mmHg (or pulse oxygen saturation of 88-92%) with evidence of end-organ dysfunction including pulmonary hypertension, congestive cardiac failure, and erythrocytosis with hematocrit > 55%.
- Also, hypoxia should be demonstrated on two occasions at least 3 weeks apart in the stable patient.

Non-invasive Ventilation:

The indications[32] for NIV in stable COPD are :

a) $PaCO_2 \geq 55$ mmHg or $PaCO_2$ of 50-54 mmHg and nocturnal desaturation (oxygen saturation by pulse oximeter ≤ 88% for continuous 5 min while receiving oxygen therapy at 2 L/min)

b) $PaCO_2$ of 50-54 mmHg and hospitalization related to recurrent (≥ 2 in a 12 month period) episodes of hypercapnic respiratory failure.

BRONCHOSCOPIC TECHNIQUES IN STABLE COPD:

Various devices like spigots, endobronchial valves and extra anatomical bypass tracts are available. Non return endobronchial valves are popular for the treatment for bullae. Lung volume reduction surgery (LVRS) is also done endoscopically by thermal vapour ablation technique.

SURGICAL TREATMENT FOR COPD:

Three primary surgical modalities are available.

Bullectomy

Bullectomy is a very old surgical procedure used to relieve dyspnea in patients with COPD. Excision of bullae that is not contributing to gas exchange is known as bullectomy. Presence of high $PaCO_2$, severe emphysematous lung and pulmonary hypertension are not a contraindication for surgery.

Lung volume reduction surgery (LVRS)

In this surgery about 20-30% of the lungs are resected bilaterally. It is safely done by median sternotomy or VATS(Video assisted thoracoscopic surgery). The remaining lung expands to fill the thorax, thereby increasing its elastic recoil pressure. It thus improves expiratory airflow. It is indicated only

when FEV_1 is more than 20% predicted and in upper lobe emphysema. It is contraindicated if FEV_1< 20% and DLCO < 20% predicted.

Lung Transplantation:

Lung transplantation will improve the quality of life in patients with very severe COPD. Lung transplantation is limited by donor organ shortage.

Criteria for lung transplantation:

BODE Index score of 7-10 in patients with age under 60 years and with at least one of the following criteria are indicated for lung transplantation.

1) History of frequent exacerbation with a high $PaCO_2$ >50mmHg.
2) Corpulmonale, pulmonary hypertension or both.
3) FEV1<20% of predicted with DL_{CO}<20% of predicted.

Lung transplantation can be unilateral or bilateral depending upon the availability of donor lung.

Presence of chronic hepatitis B or C infection, multi organ failure, current smoking and recent malignancy are considered absolute contraindications for lung transplantation surgery.

MANAGEMENT OF STABLE COPD:[33]

TREATMENT GOALS:

Reduction in current symptoms

- Relief in breathlessness and other symptoms
- Improvement in exercise tolerance
- Improvement in overall health-related quality of life

Reduction of future risk

- Prevention or slowing of disease progression
- Prevention of disease exacerbations
- Reduction in disease-related mortality

Minimizing adverse effects from treatment.

Non-Pharmacological Management of COPD:[33]

Table 8: Non pharmacological management according to GOLD guidelines.

Patient group	Essential	Recommended	Vaccines
A	Smoking cessation (can include pharmacologic treatment)	Physical activity	Flu vaccine Pneumococcal vaccine
B,C,D	Smoking cessation (can include pharmacologic treatment) Physical rehabilitation	Physical activity	Flu vaccine Pneumococcal vaccine

Pharmacological therapy for COPD:[33]

Table 9: Pharmacological therapy according to GOLD guidelines

Patient	Recommended First choice	Alternative choice	Other Possible Treatments
A	SAMA prn *or* SABA prn	LAMA *or* LABA *or* SABA and SAMA	Theophylline
B	LAMA *or* LABA	LAMA and LABA	SABA *and/or* SAMA Theophylline
C	ICS + LABA *or* LAMA	LAMA and LABA *or* LAMA and PDE4-inh. *or* LABA and PDE4-inh.	SABA *and/or* SAMA Theophylline
D	ICS + LABA *and/or* LAMA	ICS + LABA and LAMA *or* ICS+LABA and PDE4-inh. *or* LAMA and LABA *or* LAMA and PDE4-inh.	Carbocysteine N-acetylcysteine *SABA and/or* SAMA Theophylline

Table 10: Recommended first line of drugs in stable COPD



Table 11: Recommended alternate drugs in stable COPD



Table 12: Other possible treatments available



ACUTE EXACERBATION OF COPD:

An exacerbation of COPD is defined as "A sustained worsening of the patient's condition, from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD."

We should exclude other causes of worsening of symptoms like congestive cardiac failure, pneumothorax, and pulmonary embolism. Frequency and severity of acute exacerbation of COPD depends upon medication administration, smoking status, vaccination and disease severity.

Impact of acute exacerbation of COPD:

1. Acute exacerbation of COPD will produces short term and long term impact on health status, the additional decline in FEV_1 averaged approximately about 7 to 8 mL/year.

2. Acute exacerbation of COPD is major source of health care expenditure, especially when patient is admitted for hospitalization.

3. Recurrent episodes of acute exacerbation will affect the health related quality of life. Following single episode HQOL(Health-related Quality Of Life) improves over 26 weeks, acute episode has negative impact on health related quality of life.

Also, the cost of treatment is an important factor particularly for the economically backward people.

On serial CT scan imaging, exacerbations are associated with progression of emphysema. Moreover, exacerbations lead to a decline in Quality of life and it causes a economic burden on the patient.

Precipitating factors for exacerbation[34]

1) Infectious (60-80% of all exacerbations)

a) Viruses like influenza, parainfluenza,rhino and coronaviruses.

b) Bacteria- Hemophilus influenza

Steptococcus pneumonia

Moraxella catarrhalis

Pseudomonas aeruginosa

Opportunistic gram-negative species

Staphylococcus aureus

2) Environmental Factors

a) Cold air, allergens, tobacco smoke

b) Air Pollution- Both particulate and non-particulate matter for example sulfur dioxide, ozone, black smoke, and nitrogen dioxide causes acute exacerbation of COPD

3) Non-adherence to respiratory medication.

Evaluation of AE COPD:

Clinical evaluation is done to identify the cause for exacerbation, and to rule out other causes for exacerbation like congestive cardiac failure, pneumothorax, and pulmonary embolism. These conditions also produce dyspnea. Hence it is necessary to rule out these conditions.

Pathophysiology of acute exacerbation of COPD:

The factors that favours acute respiratory Failure development during AECOPD depends on following:

a) Severity of precipitating cause,
b) Degree of physiological dysfunction,
c) Subsequent physiological reserve.

Factors Leading To Fatigue Of Respiratory Muscle:



Investigations:

Chest X ray:

It is used to rule out other causes for exacerbation like parenchymal infiltration, pneumothorax, pleural effusion, cardiomegaly with pulmonary congestion and pulmonary embolism.

ECG is done to rule out cardiac problems.

Arterial blood gas analysis is used for assessment of oxygen status, carbon dioxide level and pH of blood to decide about treatment.

Sputum cultures are useful in the identification of organism that is responsible for exacerbation.

Management:

At home:

Most patients can be managed at home. Increasing the frequency of inhaled SABA for several days is effective in mild exacerbations. If patient develops severe dyspnea and if he develops change in the quantity or colour of sputum, then it indicates bacterial infection. In these conditions, patients require antibiotics.Amoxicillin and Doxycycline can be used as first line drugs. Amoxicillin/clavulanate, macrolides like azithromycin and clarithromycin,second generation cephalosporins can be used as an alternative second line agents. Fluroquinolones are better avoided. A course of Prednisolone 30-60 mg per day for 7-14 days is useful to shorten the duration of symptoms.

Indication for Hospitalisation[35]:

Symptoms

Severe dyspnea affecting day to day activities

Altered sensorium

New onset cyanosis

Signs

Use of accessory respiratory muscles

Paradoxical chest wall movements

Central cyanosis

Systolic BP < 90 mm Hg

Respiratory Rate 30/min

Heart rate> 110/min

Asterixis

Altered mental status

Spo2<90%

Others

Presence of severe comorbid conditions

Lack of social support.

Management in a hospital:

Intensification of inhaled bronchodilator treatment is done. Systemic corticosteroids and antibiotics are given. Oxygen therapy is given to maintain $PaO_2 \geq 60mmHg$ or $SpO_2 \geq 90\%$. Target oxygen saturation is 88-92%. If SpO_2 is increased beyond 92%, hypoxia induced ventilatory drive decreases and it may lead to hypoventilation resulting in further retention of CO_2.

Till early 1960, only negative pressure ventilation was used for NIV in patients with neuromuscular disorder likes poliomyelitis and deformity of chest wall. In this, negative pressure was applied over chest through tank ventilator. Later positive pressure ventilation was in use for patients with respiratory failure. Initially positive pressure was given through endo tracheal tube alone.

Non-invasive ventilation

Administration of positive or negative pressure ventilation to lung through either mask or similar device without intubation. NIV can be administered safely in the ward itself; there is no need for intensive care unit. NIV decreases mortality in patients with acute exacerbation of COPD with arterial pH of < 7.35, $PaCO_2 > 45mmhg$ (Type II respiratory failure) after medical management. It is indicated in these patients not responding to optimal medical management.

Indications:[36]

Respiratory acidosis(arterial pH< 7.35 and or pCO_2 >45 mm Hg)

Severe dyspnea

Respiratory rate > 30/min

Use of accessory muscles of respiration

Presence of paradoxical breathing

Early NIV use has reduced the rates of intubation. It has also reduced length of hospital stay . It has also caused decline in mortality among COPD patients with exacerbations. During acute exacerbation of COPD, there is an imbalance is between respiratory load and capacity of the lung, producing exaggerated inflammation in the airways leading to spasm of bronchus, edema of airways and more sputum formation. All these changes will increase the airway resistance, and lead to increase in work of breathing. Patients tend to respond with rapid, shallow, largely ineffective breath, leading to increased dead space ventilation.

Mechanical Ventilation:

If the patient does not repond to non invasive ventilation, then invasive ventilation is choosen to treat the respiratory failure.

Indications for Mechanical Ventilation[36]:

pH < 7.25

failure of NIV

Respiratory or cardiac arrest

Hemodynamic instability

Life threatening hypoxia

Heart rate< 50/min

Complications due to invasive ventilation

1. The process of intubation and mechanical ventilation like injury to teeth, upper aerodigestive tract, arrhythmia, and hypotension.

2. Loss of airway defense mechanisms and impairment of airway ciliary function facilitate an easy passage to the microorganisms and other foreign materials to lower airways allowing their colonization leading to airway inflammation and damage.

3. After removal of the endotracheal tube- hoarseness of voice, sore throat, cough, sputum production, hemoptysis, upper airway obstruction and tracheal stenosis may occur.

ASSESSMENT OF SYMPTOMS IN COPD PATIENTS:

Assessment of symptoms is an important part in COPD management.Proper identification of symptoms and its cause is necessary to prevent the morbidity and mortality associated with COPD.

In the past COPD was assessed mainly based on severity of breathlessness, so MMRC grading was in use. Now, since COPD is recognized as multisystem disease, to assess the comprehensive symptom, two questionnaires were developed .

1. CCQ (COPD Control Questionnaire). and
2. CAT questionnaire (COPD Assessment Test)

COPD Control Questionnaire (CCQ):

CCQ has 10 items in questionnaire which can be self-administered and developed to assess clinical control in patients with COPD.

COPD Assessment Test CAT SCORE [37]:

It is a patient-completed questionnaire , assessing globally the impact of COPD on health status. The CAT is quick and easy for patients to complete and, without complex calculations.

This test has an 8- uni dimensional measure to assess health status of COPD patient. CAT questionnaire is available in local languages and also through validated translations.



Your name:

Today's date:

CAT

COPD Assessment Test

How is your COPD? Take the COPD Assessment Test™ (CAT)

This questionnaire will help you and your healthcare professional measure the impact COPD (Chronic Obstructive Pulmonary Disease) is having on your wellbeing and daily life. Your answers, and test score, can be used by you and your healthcare professional to help improve the management of your COPD and get the greatest benefit from treatment.

For each item below, place a mark (X) in the box that best describes you currently. Be sure to only select one response for each question.

Example: I am very happy 0 X 2 3 4 5 I am very sad

		SCORE
I never cough	0 1 2 3 4 5 — I cough all the time	
I have no phlegm (mucus) in my chest at all	0 1 2 3 4 5 — My chest is completely full of phlegm (mucus)	
My chest does not feel tight at all	0 1 2 3 4 5 — My chest feels very tight	
When I walk up a hill or one flight of stairs I am not breathless	0 1 2 3 4 5 — When I walk up a hill or one flight of stairs I am very breathless	
I am not limited doing any activities at home	0 1 2 3 4 5 — I am very limited doing activities at home	
I am confident leaving my home despite my lung condition	0 1 2 3 4 5 — I am not at all confident leaving my home because of my lung condition	
I sleep soundly	0 1 2 3 4 5 — I don't sleep soundly because of my lung condition	
I have lots of energy	0 1 2 3 4 5 — I have no energy at all	
		TOTAL SCORE

Last Updated: February 24, 2012

Fig.12: CAT Questionnaire

Test very closely correlates with the SGRQ (St George's Respiratory Questionnaire). Range of CAT score is from 0–40. Higher scores denote a more severe impact of COPD on a patient's life.

If the score is less than 10, there is low impact. If it is between 10-20, then the impact is considered as medium. If it is between, 21-30, the impact is high and if the score is greater than 30, the impact is very high.

Various studies in CAT score:

1) A study by Hassan Ghobadi et al[38] in stable COPD patients reported a positive correlation between CAT scores and severity of the disease. In this study around 105 patients with stable COPD participated. They were given CAT questionnaire and scoring was done based on their responses. Many recent studies have correlated high CAT score with exacerbations.

2) A study by Alfredochette et al[39] reported that CAT score can also be used to quantify COPD exacerbations.They found that during exacerbation there is an increase in CAT score and during recovery there is a decrease in CAT score. It was also confirmed by a study done by Mackay et al.

3) A cross sectional study was done by Sang- do lee et al[40] in COPD patients with acute exacerbations attending out patient clinic from 19 hospitals.They found that patients with high CAT score had frequent exacerbations than the patients with low CAT score. They reported that CAT score can be used to identify patients with increased risk of exacerbations so that effective interventions can be done to prevent further exacerbations.

ASSESMENT OF DEGREE OF AIRFLOW LIMITATION:

Six Minute Walk Test:

It is an easy, simple and practical test. This test was introduced by Balke in 1963. It is approved by American Thoracic Society. It mainly measures the distance walked by the patients in 6 minutes. In the beginning, 12 Minute Walk Test was introduced . Later Butland et al introduced 6 minute walk test[41].

Indications are

Pretreatment and Posttreatment comparisons in

1. Lung transplantation
2. Lung resection
3. Lung volume reduction surgery
4. Pulmonary rehabilitation
5. COPD
6. Pulmonary hypertension
7. Heart failure

To assess the functional status in

1. COPD
2. Cystic fibrosis
3. Heart failure
4. Peripheral vascular disease
5. Fibromyalgia
6. Older patients

In addition, the 6MWT measures the submaximal level of functional capacity. Since a large number of patients may not be able to reach their maximal exercise capacity, they are allowed to opt for their own exercise intensity and stop to rest at any point during the 6MWT [42].

Contraindications:

- **Absolute**

1) Unstable angina
2) Myocardial infarction during previous month

- **Relative**

1) Resting heart rate >120/ min
2) Systolic blood pressure > 180mm Hg
3) Diastolic blood pressure > 100mm Hg

- Stable exertional angina is not a contraindication but patients having it should perform the test after taking anti angina medications and rescue nitrate medication should be readily available.

Factors influencing 6MWT:

Many factors influence the distance walked by the patients. Patients with shorter height, higher body weight tend to walk less distance than the patients with taller height and less weight. Males are found to walk more distance than the females. Patients with impaired cognition, musculoskeletal disorders and cardiovascular disorders tend to walk less distance. Patients who are highly motivated walk more distance than the less motivated ones.

Various Studies in 6MWT:

1) A study regarding 6MWT and spirometry was done by Abhijit kundu et al[43] in West Bengal. In this study, 80 patients were involved. Pre bronchodilator spirometry was done. Various spirometric indices like FEV1, FVC,PEFR, FEV1/FVC were calculated. After bronchodilation again spirometry was done and the above parameters were recorded. They found a significant correlation between 6 MWT and BODE index, also positive correlation between 6 MWT and spirometer indices.

2) A similar study was done in jaipur, Rajasthan by Manoj kumar Khandelwal et al[44]. They studied 65 COPD patients by assessing their dyspnoea (MMRC grading), GOLD criteria and also spirometer indices like PEFR, $FEF_{25-75\%}$ and correlated with 6MWD.They found a linear relationship between 6MWD and the spirometer indices and a negative correlation between 6MWD and dyspnoea.

3) A study by Sinem ilaz et al[45], reported a relation between 6MWT and nocturnal desaturation.They conducted the study in 55 COPD patients . They found that patients who desaturate during 6MWT have nocturnal desaturation during sleep. This correlation was found more in severe COPD patients than in moderate COPD patients.

4) M. Waatevik et al[46] studied 433 COPD patients and followed them for 3 years. They found that patients who desaturate after 6MWT have increased frequency of exacerbations, decline in lung function and decline in lean body mass. They also found that there is a increased risk of mortality in these patients.

AIM OF THE STUDY

AIM- Relationship between Six minute walk test, Spirometry and COPD Assessment Test (CAT) Scores in chronic obstructive pulmonary disease patients.

OBJECTIVE- : Whether Six minute walk test and CAT Score can be used as an alternative to spirometry in resource poor settings to predict the severity of COPD.

MATERIALS AND METHODS

- **SITE OF INVESTIGATION**:

  Govt. Hospital of Thoracic Medicine, Tambaram Sanatorium, Chennai.

- **STUDY PERIOD:** October 2015 to July 2016

- **STUDY DESIGN**: Prospective study.

- **STUDY POPULATION** : Outpatients and Inpatients of Government Hospital of Thoracic Medicine, Tambaram.

- **SAMPLE SIZE** :75

- **STATISTICAL ANALYSIS**: SPSS software version 19

INCLUSION CRITERIA:

a. Patients who are diagnosed as COPD by GOLD criteria.

b. Age ≥ 40 years.

EXCLUSION CRITERIA:

a. Patients with comorbid conditions like Diabetes Mellitus, Systemic hypertension, Pulmonary hypertension, Cor pulmonale, Coronary heart disease, Ischemic heart disease.

b. Active pulmonary tuberculosis

c. Treated pulmonary and extra pulmonary tuberculosis patients.

d. Patients with associated neurological disease

e. Patients with associated rheumatological disease

f. Patients with acute exacerbation of COPD.

g. Patients with peripheral vascular disease.

h. Patients who use Non invasive ventilation

i. Patients who are not willing to participate.

METHODS:

Procedure:

1.Patients were selected after applying inclusion and exclusion criterias. Informed written consent is obtained from the patients. Entire procedure is explained to them clearly.

2. A CAT respiratory questionnaire in tamil version was given to all patients and were asked to mark their symptoms scoring. The total CAT score of each patient was calculated and recorded.

3. In all patients,airflow limitation was measured as per ATS recommendations.

4. Spirometry was done and FEV_1, FVC and ratio of FEV_1/FVC were measured. Then the patient was given 200-400 microgram of salbutamol. After 15 minutes, spirometry was done again. Post bronchodilator FEV_1, FVC and FEV_1/FVC ratio were measured.

5. 6 minute walk test (6MWT) was performed according to ATS guidelines. Before the test, heart rate, blood pressure, and SpO2 measurements were done. Emergency resuscitation measures were kept ready to treat the patients, incase any complication occur during the procedure. Patients were made to walk along a 30 meters long path marked at intervals of one meter each. They were allowed to walk at their own pace. If the patient developed any symptom of chest pain,severe dyspnea, or leg pain, they were allowed to

rest during the test. Then they were allowed to continue. The patients were encouraged to complete the test.

The patients were asked to stop after 6 minutes. After the test was over, again heart rate, blood pressure and SpO2 measurements were done. Distance walked by the patient at the end of 6 minutes was recorded in meters.

6. For each patient, points obtained in CAT Score, Spirometric indices

(FEV_1,FVC, FEV_1 / FVC) and the distance walked in Six minute walk test were compared and analysed.

ETHICAL JUSTIFICATION

The various investigations and procedures that were used in this study was as per protocol. The identity of each patient was kept confidential. This study did not violate medical ethics in anyway and it was meant to know the relationship between Six minute walk test, Spirometry and COPD Assessment Test (CAT) Scores in chronic obstructive pulmonary disease patients.

OBSERVATION AND RESULTS

Total number of 75 patients were enrolled in this study, of which female were 13.3% and males were 86.7%

Table 13: Age & Sex distribution of study population

Age Distribution in years	Male (%)	Female (%)	Total (%)
40-44	3(4)	1(1.3)	4(5.3)
45-49	6(8)	2(2.7)	8(10.7)
50-54	3(4)	1(1.3)	4(5.3)
55-59	12(16)	2(2.7)	14(18.7)
>60	41(54.7)	4(5.3)	45(60)
Total	65(86.7)	10(13.3)	75(100)

CHART NO: 1



CHART NO : 2

Age and sex distribution of study population



As seen above, most of the patients were above 60 years of age and 86.7% of study population were males.

All these 75 patients had met our inclusion criteria. Spirometry was done according to GOLD criteria.

Table 14: GOLD Staging of the study population

Severity of symptoms	FEV_1%	Number of patients	Percentage
Mild (Stage I)	>80	4	5.3
Moderate (Stage II)	50-80	18	24
Severe (Stage III)	30-50	42	56
Very Severe (Stage IV)	<30	11	14.7

CHART NO : 3



In the above chart, we can see that 4 patients are grouped in STAGE I, 18 patients are grouped in STAGE II, 42 patients are grouped in STAGE III and 11 patients are grouped in STAGE IV.

CAT questionnaire was given to all these patients and CAT score was calculated.

Table 15: Correlation between the number of patients in various GOLD stages and their mean CAT score

	GOLD I	GOLD II	GOLD III	GOLD IV
Number of patients	4	18	42	11
CAT score (Mean±SD)	10.25±0.95	19.55±5.42	21.04±4.76	23.63±3.47
P VALUE < 0.001				

CHART NO: 4



4 patients in STAGE I had a mean score of 10.25±0.95

18 patients in STAGE II had a mean CAT score of 19.55±5.42

42 patients in STAGE III had a mean CAT score of 21.04±4.76

11 patients in STAGE IV had a mean CAT score of 23.63±3.47

In all these patients, six minute walk test (6MWT) was performed. Distance covered by the patients(6MWD) was measured and correlated with different parameters of spirometry.

Table 16- 6MWD by patients in different stages

Severity of symptoms	FEV_1%	Number of patients	6MWD
Mild (Stage I)	>80	4	482.5±11.9 METERS
Moderate (Stage II)	50-80	18	429.8±76.6 METERS
Severe (Stage III)	30-50	42	360.5±80.3 METERS
Very Severe (Stage IV)	<30	11	293.3±84.4 METERS
F –Ratio = 9.905, p<0.001			

Table 17: Distribution of patients in different subgroups of 6 MWD (meters)

6MWD (Meters)	I (%)	II (%)	III (%)	IV (%)	Total (%)
101-200	0 (0)	0 (0)	1 (1.3)	1 (1.3)	2 (2.7)
201-300	0 (0)	1 (1.3)	7 (9.3)	6 (8)	14 (18.7)
301-400	0 (0)	5 (6.7)	25 (33.3)	4 (5.3)	34 (45.3)
>401	4 (5.3)	12 (16)	9 (12)	0 (0)	25 (33.3)
Total (%)	4 (5.3)	18 (24)	42 (56)	11 (14.7)	75 (100)

CHART NO: 5



Table 18: Correlation between 6MWD with Spirometric indices

	Six minute walk test (meter)			
	Range	Mean±SD	Pearson correlation	P value
Post FEV1	18.1-83	43.69±15.12	0.561	<0.001
Post FVC	30.6-95	59.48±15.65	0.341	0.003
Post FEV_1/FVC	0.28-0.77	0.56±0.11	0.476	<0.001

CHART 6: Scatter diagram comparing 6-minute walk distance with post-FEV_1



The scatter diagram shows a positive slope which indicates there is a positive correlation between 6 MWD and post FEV_1.

CHART 7 : Scatter diagram comparing 6-minute walk distance with CAT SCORE



The scatter diagram shows negative slope which indicates patients with high CAT score i.e, patients with severe disease walk less distance.

DISCUSSION

In our study, there is a positive correlation of 6MWD with post FEV_1& FVC. Among 75 patients, 6MWD of 4 patients in stage I GOLD classification was 482.5± 11.9 meters. 6MWD of 18 patients in stage II GOLD classification was 429.8± 76.6 meters. 6MWD of 42 patients in stage III was 360.5± 80.3 meters. 6MWD of 11 patients in stage IV was 293.3± 84.4 meters. P value < 0.001(statistically significant).

Post bronchodilator FEV_1 was compared with 6MWD. We got pearson correlation as 0.561 and a P value of < 0.001 which is statistically significant. It shows a positive correlation between FEV_1 and 6MWD. Similarly post bronchodilator FVC was compared with 6MWD.We got pearson correlation as 0.341 and a P value of 0.003 which is statistically significant. It shows a positive correlation between FVC and 6MWD. Also, Post bronchodilator FEV_1/FVC was compared with 6MWD, we got a Pearson correlation as 0.476 and P value < 0.001.It is compatible with the study published by chulmsky et al.

Our study is compatible with studies of Roozbeh *et al*., Mehta and Kumari, and Carter *et al*., which also showed association between 6MWT and expiratory volumes in COPD.

In our study we find a positive correlation between severity of COPD and CAT score. Scores increase as the stage increases i.e, patients with more severe COPD had higher CAT scores. It is compatible with the study by Jones PW et al, which analysed the properties of CAT Score in a cross sectional European study.

LIMITATIONS:

a) Our sample size was small.

b) Only 13.3% of our study population were females. So we could not find out the exact correlation in female population.

c) 6 MWT may be affected by a variety of factors like age,sex,height and weight. We did not adjust these parameters while calculating 6 MWD.

CONCLUSION

From this study we conclude that 6 minute walk test can be used as an alternate tool to assess the severity of COPD. Every time spirometry is not needed to assess the severity of COPD. However Spirometry is necessary to diagnose COPD. CAT score can be used to assess the impact of COPD on health status and quality of life. Both 6MWT and CAT score can be used even in a rural setting where most of the COPD patients have no access to spirometry.

BIBLIOGRAPHY

BIBLIOGRAPHY:

1. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1965; 1 : 775-9.
2. American Thoracic Society. Definitions and classification of chronic bronchitis, asthma and pulmonary emphysema. Am Rev Respir Dis 1962; 85 : 762-7.
3. Snider GL, Kleinerman J, Thurlbeck WM, Bengali ZH. The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of lung Diseases, workshop. Am Rev Respir Dis 1985; 132 : 182-5.
4. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011; 365 : 1567-75.
5. Mitzer W. Emphysema - a disease of small airways or lung parenchyma N Engl J Med 2011; 365 : 1637-9.
6. Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, et al. European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001; 18 : 85-92.

7. Halbert R J, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28 : 523-32.

8. Mahesh PA, Jayaraj BS, Prahlad ST, Chaya SK, Prabhakar AK, Agarwal AN, et al. Validation of a structured questionnaire for COPD and prevalence of COPD in rural area of Mysore: A pilot study. Lung India. 2009;26:63–9

9. Salvi S, Juvekar S, Londhe J, Brashier B, Madas S, Barnes PJ. Prevalence of COPD in a rural population in India. Eur Respir J 2011;p. 2954

10. Buist A S, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370 : 741-50

11. S.K. Jindal, D. Gupta, A.N. Agarwal. Guidelines for management of Chronic Obstructive Pulmonary Disease in India: A guide for physicians (2003).

12. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2015

13. Fore y BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med 2011; 11: 36.

14. Lindberg A, Eriksson B, Larsson LG, Rönmark E, Sandström T, Lundbäck B, et al. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 2006; 129: 879-85.
15. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-9.
16. Jindal S. K, Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D, et al. Asthma Epidemiology Study Group. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. Indian J Chest Dis Allied Sci 2006; 48: 23-9.
17. Bjartveit K, Tverdal A. Health consequences of smoking 1-4 cigarettes per day. Tobacco Control. 2005;14:315–20.
18. Nicholas R .Anthonisen "Lessons from the Lung Health study", Proceedings of the American Thoracic Society, Vol. 1, Exacerbations in COPD and asthma: mechanisms and medicine (2004), pp. 143-145.
19. Hnizdo E, Sullivan PA, Bang KM, Wagner G. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: A study of data from the Third National Health and Nutrition Examination Survey.Am J Epidemiology. 2002;156:738–46.

20. Chhabra SK, Chhabra P, Rajpal S, Gupta RK. Ambient air pollution and chronic respiratory morbidity in Delhi. Arch Environ Health. 2001;56:58–64

21. Kan H, Heiss G, Rose KM, 37. Whitsel E, Lurmann F, London SJ, et al. Traffic exposure and lung function in adults: the Atherosclerosis Risk in Communities study. Thorax 2007; 62: 873-9.

22. Decramer M, Janssens W, Miravitlles M. Chronic obstructive Pulmonary disease. Lancet 2012; 379: 1341-51

23. Cardoso WV, Sekhon HS, Hyde DM, et al.: Collagen and elastin in human pulmonary emphysema. Am Rev Respir Dis 147:975–981, 1993

24. Site and nature of airway obstruction in chronic obstructive lung disease Hogg JC, Macklem PT, Thurlbeck WM N Engl J Med. 1968 Jun 20; 278(25):1355-60.

25. Tokuda Y, Miyagi S. Physical diagnosis of chronic obstructive pulmonary disease. Intern Med. 2007;46:1885–91.

26. Goddard PR, Nicholson EM, Laszlo G, Watt I (1982) Computed tomography in pulmonary emphysema. Clin Radiol 33:379-87

27. Cavigli E, Camiciottoli G, Diciotti S, et al. Whole-lung densitometry versus visual assessment of emphysema. Eur Radiol. 2009; 197:1686-1692

28. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease Bartolome R. Celli, M.D., Claudia G. Cote, M.D., Jose M. Marin, M.D., Ciro Casanova, M.D., Maria Montes de Oca, M.D., Reina A. Mendez, M.D., Victor Pinto

Plata, M.D., and Howard J. Cabral, Ph.D. N Engl J Med 2004; 350:1005-1012

29. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, and Donohue JF: Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 1989 ; 139 : 1188-91

30. Gregory Feldman et al.Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

31. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–413.

32. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation: A consensus conference report. Chest.

33. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2015

34. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–21

35. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations Lung India. 2013 Jul-Sep; 30(3): 228–267.

36. Sharma S, Agarwal R, Aggarwal AN, Gupta D, Jindal SK. A survey of noninvasive ventilation practices in a respiratory ICU of North India. Respir Care. 2012;57:1145–53.

37. Gruffydd-Jones K, Marsden HC, Holmes S, Kardos P, Escamilla R, Dal Negro R, Roberts J, Nadeau G, Vasselle M, Leather DA, and Jones P: Utility of COPD Assessment test (CAT) in primary care consultations: a randomized controlled study. Prim Care Respir J 2013, 22(1):37-43

38. Hassan Ghobadi et al, The Relationship between COPD Assessment Test (CAT) Scores and Severity of Airflow Obstruction in Stable COPD Patients. Tanaffos 2012; 11(2): 22–26.

39. Alfredochette et al The COPD Assessment Test in the Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations Expert Rev Resp Med. 2012;6(4):373-375.

40. Sang do – lee et al, The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. Resmed journal April 2014 Volume 108, Issue 4, Pages 600–608

41. Cooper KH. A means of assessing maximal oxygen intake: Correlation between field and treadmill testing. JAMA 1968;203:201-4.

42. World Health Organisation. The GOLD global strategy for the management and prevention of COPD.

43. Abhijit kundu et al. Correlation of six minute walk test with spirometric indices in chronic obstructive pulmonary disease patients: A tertiary care hospital experience .The Journal of Association of Chest Physicians | Jan-Jun 2015 | Vol 3 | Issue 1

44. Manoj Kumar Khandelwal et al.Six minute walk distance: Correlation with spirometric & clinical parameters in chronic obstructive pulmonary disease. International J. of Healthcare & Biomedical Research, Volume: 1, Issue : 3, April 2013, Pages 217-226

45. Sinem ilaz et al, Does the 6-minute walk test predict nocturnal oxygen desaturation in patients with moderate to severe COPD? Chron resp dis 2015 Feb;12(1):61-8.

46. M. Waatevik et al. Oxygen desaturation in 6-min walk test is a risk factor for adverse outcomes in COPD.European respiratory journal 2016 Jul;48(1):82-91

ANNEXURES

PROFORMA

- Name :
- Age :
- Gender :
- Height/Weight :
- Previous history of

  Tuberculosis treatment :
- History suggestive of heart disease :
- History of Neurological disease :
- History of Rheumatological disease :
- Thorough clinical examination :
- Investigations :

  Chest X-ray,

  ECG,

  Spo2,

  Blood pressure,

  CAT questionnaire,

  Spirometry,

  Six minute walk test,

CONSENT FORM

I Mr / Mrs / Miss / _____ have understood the procedure read by the Doctors. I in my whole conscious awareness give consent for the procedure. I understand that the procedure is done in good faith for the best therapeutic results possible. I fully understand the consequences of the procedure. I can resign from the study at any point of time.

Signature

Name :

Date and Time :

Signature of Researcher :

<u>சுயஒப்புதல் படிவம்</u>

<u>ஆய்வு செய்யப்படும் தலைப்பு</u>:

நாள்பட்ட நுரையீரல் அடைப்பு நோய் உள்ளவர்களில் 6 நிமிட நடைபயிற்சி ஆய்வு மற்றும் CAT மதிப்பெண் ஆய்வு

ஆராய்ச்சி நிலையம்: அரசு நெஞ்சகநோய் மருத்துவமனை , தாம்பரம்சானடோரியம், சென்னை.

பங்குபெறுபவரின் பெயர்:

பங்குபெறுபவரின் எண் :

பங்குபெறுபவர் ( ) இதனைக்குறிக்கவும் :

மேலேகுறிப்பிடப்பட்டுள்ள ஆய்வின்விவரங்கள்எனக்குவிளக்கப்பட்டது.

என்னுடைய சந்தேகங்களைக் கேட்கவும், அதற்க்கான தகுந்த விளக்கங்களைப் பெறவும் வாய்ப்பளிக்கப்பட்டது .நான் இவ்வாய்வில் தன்னிச்சையாகத்தான் பங்கேற்கிறேன். எந்த காரணத்தினாலோ எந்த கட்டத்திலும் எந்த சட்டச்சிக்கலுக்கும் உட்படாமல் நான் இவ்வாய்வில் இருந்துவிலகிக் கொள்ளலாம் என்றும் அறிந்துகொண்டேன். ☐

இந்த ஆய்வு சம்பந்தமாகவோ ,இதைச்சார்ந்த மேலும் ஆய்வு மேற்கொள்ளும்போதும் இந்த ஆய்வில் பங்குபெறும் மருத்துவர் என்னுடைய மருத்துவ அறிக்கையை பார்ப்பதற்கு என் அனுமதி தேவையில்லை என அறிந்துகொள்கிறேன். நான் ஆய்வில் இருந்து விலகிக்கொண்டாலும் இது பொருந்தும் என அறிகிறேன். ☐

இந்த ஆய்வு மூலம் கிடைக்கும் தகவல்களையும் பரிசோதனை முடிவுகளையும் மற்றும் சிகிச்சை தொடர்பான தகவல்களையும் மருத்துவர் மேற்க்கொள்ளும் ஆய்வில் பயன்படுத்திக்கொள்ளவும் அதைப்பிரசுரிக்கவும் என் முழுமனதுடன் சம்மதிக்கிறேன . ☐

இந்த ஆய்வில் பங்குகொள்ள ஒப்புக்கொள்கிறேன். எனக்கு கொடுக்கப்பட்ட அறிவுரைப்படி நடந்துகொள்வதுடன் இந்த ஆய்வை மேற்கொள்ளும் மருத்துவ அணிக்கு உன்னமையுடன் இருப்பேன் என்று உறுதி அளிக்கின்றேன். என் உடல்நலம் பாதிக்கப்பட்டாலோ அல்லது எதிர்பாராத வழக்கத்திற்கு மாறான நோய்க்குறிதென்பட்டாலோ உடனே அதை மருத்துவ அணிக்கு தெரிவிப்பேன் என உறுதி அளிக்கிறேன் . ☐

பங்குபெறுபவரின்கையொப்பம் ---------- இடம் ---------- தேதி ----------

கட்டைவிரல் ரேகை

பங்குபெறுபவரின் பெயர் மற்றும் விலாசம் ----------

ஆய்வாளரின் கையொப்பம் ----------இடம் ---------- தேதி ----------

ஆய்வாளரின் பெயர் ----------

நோயாளிக்கான தகவல் படிவம்

மதிப்பிற்குரிய ஐயா / அம்மையீர்,

உங்கள் விருப்பத்தின் பேரில் **"நாள்பட்ட நுரையீரல் அடைப்பு நோய் உள்ளவர்களில் 6 நிமிட நடைபயிற்சி ஆய்வு மற்றும் CAT மதிப்பெண்"** பற்றிய ஆய்வில் பங்கேற்கும்படி அன்புடன் கேட்டுக்கொள்கிறோம். இந்த ஆய்வில் ஆரய்ச்சி நோக்கத்துக்காக தாங்கள் பரிசோதனைக்கு உட்படுத்தப்படுவீர்கள். தகுந்த சிகிச்சை தங்களுக்கு தொடங்கப்படும். தங்களுக்கு இந்த ஆய்வில் பங்கேற்க விருப்பம் இருந்தால் தாங்கள் அருள்கூர்ந்து ஒப்புதல் படிவத்தைப் படித்துப்பார்த்துக் கையொப்பம் இடும்படிக் கேட்டுக்கொள்கிறேன்.

உங்கள் பெயர்:

இன்றைய தேதி:

COPD Assessment Test

உங்களுடைய சிஓபிடி (நாள்பட்ட நுரையீரல் அடைப்பு நோய்) எப்படியிருக்கிறது? சிஓபிடி மதிப்பீட்டுச் சோதனையைச் [COPD Assessment Test™] (சிஏடி) மேற்கொள்ளவும்

இந்தக் கேள்வித்தொகுப்பு, உங்களுக்கும் மற்றும் உங்களுடைய உடல்நலக்கவனிப்பு தொழில்முறை வல்லுனருக்கும் உங்கள் நலவாழ்வு மற்றும் தினசரி வாழ்க்கையின் மீது சிஓபிடி **(நாள்பட்ட நுரையீரல் அடைப்பு நோய்)** ஏற்படுத்திக்கொண்டிருக்கிற விளைவினை அளவீடு செய்வதற்கு உதவும். உங்களுடைய சிஓபிடி நிர்வாகத்தினை மேம்படுத்துவதற்கு உதவிடவும் மற்றும் சிகிச்சையிலிருந்து மிகவும் அதிகமான நன்மையினைப் பெறுவதற்கும் உங்களாலும் மற்றும் உங்கள் உடல்நலக்கவனிப்பு தொழில்முறை வல்லுனராலும் உங்களுடைய பதில்கள் மற்றும் சோதனை மதிப்பெண்கள் பயன்படுத்தப்பட முடியும்.

கீழ்க்காணும் ஒவ்வொரு ஜட்டத்திற்கும், தற்பொழுது உங்களை மிகச்சிறப்பாக விவரிக்கிற பெட்டியில் ஒரு குறியை (X) இடவும். ஒவ்வொரு கேள்விக்கும் நிச்சயமாக ஒரு பதிலை மட்டுமே தேர்வு செய்யவும்.

உதாரணம்: நான் மிகவும் மகிழ்ச்சியாயிருக்கிறேன்.	0 **X** 1 2 3 4 5	நான் மிகவும் சோகமாக இருக்கிறேன்.	
நான் ஒருபோதும் இருமுவதில்லை	0 1 2 3 4 5	நான் எப்பொழுதும் இருமுகிறேன்	
என் மார்பில் சளி (கபம்) சிறிதும் இல்லை	0 1 2 3 4 5	என் மார்பு முழுமையாக சளி (கபம்) நிறைந்திருக்கிறது	
என் மார்பு இறுக்கமாய் உணர்வதே இல்லை	0 1 2 3 4 5	என் மார்பு மிகவும் இறுக்கமாய் உணர்கிறது	
நான் ஒரு குன்றின் மீது அல்லது மாடிப்படிகளில் நடந்து ஏறும்பொழுது எனக்கு மூச்சுத்திணறல் இல்லை	0 1 2 3 4 5	நான் ஒரு குன்றின் மீது அல்லது மாடிப்படிகளில் நடந்து ஏறும்பொழுது எனக்கு மிகவும் மூச்சுத்திணறல் இருக்கிறது	
வீட்டில் நான் எந்த நடவடிக்கைகள் செய்வதிலும் மட்டுப்படுத்தப்படவில்லை	0 1 2 3 4 5	வீட்டில் நான் நடவடிக்கைகள் செய்வதில் மிகவும் மட்டுப்படுத்தப்படுகிறேன்	
என்னுடைய நுரையீரல் பிரச்சினை இருக்கிற போதிலும்கூட நான் என் வீட்டிலிருந்து வெளியே செல்வதில் தன்னம்பிக்கையுடன் இருக்கிறேன்	0 1 2 3 4 5	என்னுடைய நுரையீரல் பிரச்சினை காரணமாக நான் என் வீட்டிலிருந்து வெளியே செல்வதில் சிறிதும் தன்னம்பிக்கை இல்லாதிருக்கிறேன்	
நான் ஆழமாக உறங்குகிறேன்	0 1 2 3 4 5	என்னுடைய நுரையீரல் பிரச்சினை காரணமாக நான் ஆழமாக உறங்குவதில்லை	
நான் ஏராளமான சக்தி படைத்துள்ளேன்	0 1 2 3 4 5	எனக்குச் சிறிதும் சக்தி இல்லை	
		மொத்த மதிப்பெண்	

மதிப்பெண்

MASTER CHART

S. NO	NAME	AGE	SEX	CAT SCORE	IMPACT LEVEL
1	MANNU	75	M	21	HIGH
2	GOVINDASAMY	42	M	20	MEDIUM
3	RAJA	55	M	20	MEDIUM
4	SRINIVASAN	58	M	9	LOW
5	RAJU	42	M	10	MEDIUM
6	JOSEPH	70	M	21	HIGH
7	VELAYUTHAM	75	M	25	HIGH
8	GOVINDASWAMY	67	M	11	MEDIUM
9	KOTHANDAM	54	M	11	MEDIUM
10	RANGANATHAN	62	M	17	MEDIUM
11	SUBRAMANI	60	M	29	HIGH
12	SAMPATH KUMAR	67	M	31	VERY HIGH
13	MUTHU	45	M	25	HIGH
14	RAJI	46	M	24	HIGH
15	PERUMAL	57	M	29	HIGH
16	ABDUL HAMEED	48	M	29	HIGH
17	MATHIALAGAN	55	M	27	HIGH
18	PARVATHY	75	F	29	HIGH
19	ELLAMMAL	52	F	29	HIGH
20	PERIAYASAMY	65	M	28	HIGH
21	SAROJA	46	F	30	HIGH
22	ARUNA	40	F	24	HIGH
23	RAJENDRAN	64	M	22	HIGH
24	KRISHNAN .D	62	M	18	HIGH
25	YETTIAPPAN	62	M	26	HIGH
26	KANNIYAPPAN	63	M	24	HIGH
27	MURUGAN	80	M	20	MEDIUM
28	AYYAPPAN	63	M	30	HIGH
29	GOPAL	58	M	27	HIGH
30	SRINIVASAN	75	M	25	HIGH
31	KUMAR	49	M	13	MEDIUM
32	ARUMUGAM	67	M	22	HIGH

33	RAJESHWARI	70	F	26	HIGH
34	BANAKALU	72	M	20	MEDIUM
35	RAYARATHINAM	73	M	23	HIGH
36	GUNASEKAR	45	M	23	HIGH
37	SRINIVASAN	70	M	23	HIGH
38	SELVI	57	F	25	HIGH
39	NALLATHAMBI	59	M	20	MEDIUM
40	CHAKKARADARI	70	M	24	HIGH
41	AYYASAMY.P	52	M	19	MEDIUM
42	RADHAMMAL	75	F	21	HIGH
43	KANNAMAL	85	F	19	MEDIUM
44	AYYASAMY.S	55	M	18	MEDIUM
45	VEERABATHIRAN	60	M	21	HIGH
46	SAMUVEL	70	M	22	HIGH
47	GANAPATHY	55	M	24	HIGH
48	VISWANATHAN	45	M	13	MEDIUM
49	VELAYUDHAM	60	M	22	HIGH
50	KANNAN	60	M	16	MEDIUM
51	GAJAPATHY	60	M	18	MEDIUM
52	RAMAMOORTHY	74	M	21	HIGH
53	SUNDARRAJ	60	M	16	MEDIUM
54	MURUGESAN	67	M	18	MEDIUM
55	GAJENDRAN	61	M	13	MEDIUM
56	IRULANDI	67	M	16	MEDIUM
57	GOPAL	72	M	16	MEDIUM
58	VENUGOPAL	55	M	17	MEDIUM
59	THANGAVEL	65	M	21	HIGH
60	SATHYA	55	F	19	MEDIUM
61	SENTHIL KUMAR	42	M	18	MEDIUM
62	ARUNAGIRI	75	M	17	MEDIUM
63	VARADHAN	55	M	22	HIGH
64	CHINNASAMY	65	M	12	MEDIUM
65	MANIMEGALAI	48	F	19	MEDIUM
66	DHANDAPANI	62	M	13	MEDIUM
67	LAKSHMANAN	59	M	13	MEDIUM

68	AYYANAR	70	M	12	MEDIUM
69	VEDHACHALAM	70	M	16	MEDIUM
70	SELVAN	62	M	15	MEDIUM
71	KANNIAYAPPAN	55	M	20	MEDIUM
72	IYYAPAN	63	M	21	HIGH
73	KRISHNAN	50	M	23	HIGH
74	MURUGESAN	62	M	16	MEDIUM
75	VASUDEVAN	65	M	20	MEDIUM

S. NO	NAME	AGE	SEX	POST FEVI/FVC	POST FVC%	POST FEV1%	GOLD STAGING	6 MWD IN METRES
1	MANNU	75	M	0.343	61	29	IV	260
2	GOVINDASAMY	42	M	0.484	51	30	III	230
3	RAJA	55	M	0.578	63	47	III	320
4	SRINIVASAN	58	M	0.689	87	81	I	490
5	RAJU	42	M	0.69	90	82	I	495
6	JOSEPH	70	M	0.6897	43	38.5	III	340
7	VELAYUTHAM	75	M	0.458	59	34	III	230
8	GOVINDASWAMY	67	M	0.691	92	81	I	475
9	KOTHANDAM	54	M	0.688	91	83	I	470
10	RANGANATHAN	62	M	0.692	65	62.9	II	510
11	SUBRAMANI	60	M	0.6923	42.4	37.1	III	420
12	SAMPATH KUMAR	67	M	0.5962	59.8	45.9	III	330
13	MUTHU	45	M	0.58	42.1	29.1	IV	290
14	RAJI	46	M	0.6524	58	47.2	III	580
15	PERUMAL	57	M	0.6867	51.1	45.1	III	280
16	ABDUL HAMEED	48	M	0.5355	38.1	24.4	IV	398
17	MATHIALAGAN	55	M	0.4804	30.6	18.1	IV	358
18	PARVATHY	75	F	0.675	40.8	34.2	III	325
19	ELLAMMAL	52	F	0.6771	42.9	34.6	III	340
20	PERIAYASAMY	65	M	0.6797	59.3	50.7	II	520
21	SAROJA	46	F	0.6957	62.4	51.1	II	540
22	ARUNA	40	F	0.6591	46.2	36.2	III	350
23	RAJENDRAN	64	M	0.6842	37.1	32.2	III	380
24	KRISHNAN .D	62	M	0.6211	46.8	36.9	III	400
25	YETTIAPPAN	62	M	0.6265	48.7	38.7	III	465
26	KANNIYAPPAN	63	M	0.6692	40.7	34.5	III	481

27	MURUGAN	80	M	0.6429	37.3	32.6	III	450
28	AYYAPPAN	63	M	0.5323	54.4	36.8	III	160
29	GOPAL	58	M	0.6765	71.1	66.7	II	540
30	SRINIVASAN	75	M	0.6429	68.9	58.7	II	480
31	KUMAR	49	M	0.612	81	63	II	448
32	ARUMUGAM	67	M	0.6134	36.3	28.6	IV	265
33	RAJESHWARI	70	F	0.56	48.7	23.7	IV	278
34	BANAKALU	72	M	0.61	76	65	II	290
35	RAYARATHINAM	73	M	0.481	48	33	III	260
36	GUNASEKAR	45	M	0.59	89	53	II	400
37	SRINIVASAN	70	M	0.4	54	30	III	380
38	SELVI	57	F	0.54	33	24	IV	380
39	NALLATHAMBI	59	M	0.61	62	45	III	385
40	CHAKKARADARI	70	M	0.59	49	40	III	400
41	AYYASAMY.P	52	M	0.613	69	55	II	403
42	RADHAMMAL	75	F	0.474	55	36	III	360
43	KANNAMAL	85	F	0.5	70	51	II	344
44	AYYASAMY.S	55	M	0.688	48	43	III	480
45	VEERABATHIRAN	60	M	0.521	58	40	III	400
46	SAMUVEL	70	M	0.465	57	37	III	240
47	GANAPATHY	55	M	0.445	51	29	IV	120
48	VISWANATHAN	45	M	0.59	86	65	II	423
49	VELAYUDHAM	60	M	0.5	60	40	III	383
50	KANNAN	60	M	0.514	62	42	III	394
51	GAJAPATHY	60	M	0.488	65	42	III	360
52	RAMAMOORTHY	74	M	0.534	59	44	III	380
53	SUNDARRAJ	60	M	0.385	57	29	IV	397
54	MURUGESAN	67	M	0.539	45	33	III	263
55	GAJENDRAN	61	M	0.521	61	42	III	336
56	IRULANDI	67	M	0.454	65	40	III	380
57	GOPAL	72	M	0.363	69	35	III	240
58	VENUGOPAL	55	M	0.581	61	55	II	354
59	THANGAVEL	65	M	0.647	61	53	II	360
60	SATHYA	55	F	0.607	69	54	II	307
61	SENTHIL KUMAR	42	M	0.484	51	30	III	326
62	ARUNAGIRI	75	M	0.343	69	59	II	436
63	VARADHAN	55	M	0.28	72	26	IV	240
64	CHINNASAMY	65	M	0.482	95	69	II	478
65	MANIMEGALAI	48	F	0.58	47	35	III	390
66	DHANDAPANI	62	M	0.567	53	40	III	454
67	LAKSHMANAN	59	M	0.596	53	42	III	360
68	AYYANAR	70	M	0.663	77	70	II	465
69	VEDHACHALAM	70	M	0.396	75	41	III	370
70	SELVAN	62	M	0.351	90	42	III	438

71	KANNIAYAPPAN	55	M	0.617	80	65	II	438
72	IYYAPAN	63	M	0.462	57	35	III	316
73	KRISHNAN	50	M	0.487	32	20	IV	240
74	MURUGESAN	62	M	0.469	64	40	III	352
75	VASUDEVAN	65	M	0.404	60	33	III	414

S. NO	NAME	AGE	SEX	BEFORE 6MWT		
				PULSE RATE/MIN	SPO2 %	BP IN mm Hg
1	MANNU	75	M	98	98	130/80
2	GOVINDASAMY	42	M	92	99	126/80
3	RAJA	55	M	84	96	134/78
4	SRINIVASAN	58	M	80	97	126/86
5	RAJU	42	M	82	95	136/82
6	JOSEPH	70	M	92	96	136/78
7	VELAYUTHAM	75	M	84	98	128/82
8	GOVINDASWAMY	67	M	96	97	136/78
9	KOTHANDAM	54	M	78	97	118/78
10	RANGANATHAN	62	M	90	98	120/80
11	SUBRAMANI	60	M	92	98	128/76
12	SAMPATH KUMAR	67	M	84	99	136/76
13	MUTHU	45	M	88	96	132/78
14	RAJI	46	M	96	98	126/82
15	PERUMAL	57	M	78	97	134/86
16	ABDUL HAMEED	48	M	80	96	132/82
17	MATHIALAGAN	55	M	78	95	126/78
18	PARVATHY	75	F	90	94	118/68
19	ELLAMMAL	52	F	78	97	126/78
20	PERIAYASAMY	65	M	74	98	128/78
21	SAROJA	46	F	78	99	136/76
22	ARUNA	40	F	76	96	126/84
23	RAJENDRAN	64	M	72	99	136/78
24	KRISHNAN .D	62	M	68	95	138/80
25	YETTIAPPAN	62	M	90	96	118/86
26	KANNIYAPPAN	63	M	88	97	128/86
27	MURUGAN	80	M	98	96	134/86
28	AYYAPPAN	63	M	78	99	126/78
29	GOPAL	58	M	76	94	134/76

30	SRINIVASAN	75	M	98	96	136/76
31	KUMAR	49	M	90	98	134/74
32	ARUMUGAM	67	M	88	96	112/78
33	RAJESHWARI	70	F	86	99	118/78
34	BANAKALU	72	M	80	96	126/84
35	RAYARATHINAM	73	M	86	94	116/80
36	GUNASEKAR	45	M	78	97	116/78
37	SRINIVASAN	70	M	80	98	116/80
38	SELVI	57	F	88	99	114/76
39	NALLATHAMBI	59	M	96	96	126/78
40	CHAKKARADARI	70	M	78	97	124/80
41	AYYASAMY.P	52	M	76	99	126/78
42	RADHAMMAL	75	F	76	96	124/78
43	KANNAMAL	85	F	78	97	136/76
44	AYYASAMY.S	55	M	80	99	132/74
45	VEERABATHIRAN	60	M	88	98	126/76
46	SAMUVEL	70	M	84	97	116/78
47	GANAPATHY	55	M	86	97	128/76
48	VISWANATHAN	45	M	76	96	134/82
49	VELAYUDHAM	60	M	90	99	110/80
50	KANNAN	60	M	76	96	114/82
51	GAJAPATHY	60	M	86	97	116/78
52	RAMAMOORTHY	74	M	88	96	118/76
53	SUNDARRAJ	60	M	90	97	116/76
54	MURUGESAN	67	M	84	98	126/74
55	GAJENDRAN	61	M	88	99	118/80
56	IRULANDI	67	M	68	96	132/80
57	GOPAL	72	M	70	97	110/80
58	VENUGOPAL	55	M	76	96	126/82
59	THANGAVEL	65	M	72	97	130/80
60	SATHYA	55	F	78	98	120/80
61	SENTHIL KUMAR	42	M	84	96	110/80
62	ARUNAGIRI	75	M	82	97	134/72
63	VARADHAN	55	M	86	99	118/78
64	CHINNASAMY	65	M	92	98	134/78
65	MANIMEGALAI	48	F	96	97	124/74
66	DHANDAPANI	62	M	84	98	130/80

67	LAKSHMANAN	59	M	86	99	120/80
68	AYYANAR	70	M	82	96	126/76
69	VEDHACHALAM	70	M	86	98	132/72
70	SELVAN	62	M	90	96	124/76
71	KANNIAYAPPAN	55	M	84	97	126/78
72	IYYAPAN	63	M	82	98	128/84
73	KRISHNAN	50	M	80	99	118/78
74	MURUGESAN	62	M	78	97	132/82
75	VASUDEVAN	65	M	76	98	130/80

S. NO	NAME	AGE	SEX	AFTER 6MWT		
				PULSE RATE/MIN	SPO2 %	BP IN mm Hg
1	MANNU	75	M	102	98	132/80
2	GOVINDASAMY	42	M	96	96	126/80
3	RAJA	55	M	90	96	134/78
4	SRINIVASAN	58	M	86	97	130/86
5	RAJU	42	M	88	94	136/84
6	JOSEPH	70	M	98	98	136/78
7	VELAYUTHAM	75	M	90	98	130/84
8	GOVINDASWAMY	67	M	98	96	136/78
9	KOTHANDAM	54	M	88	97	120/78
10	RANGANATHAN	62	M	98	96	120/80
11	SUBRAMANI	60	M	96	96	130/76
12	SAMPATH KUMAR	67	M	88	99	136/78
13	MUTHU	45	M	98	98	130/76
14	RAJI	46	M	100	96	130/80
15	PERUMAL	57	M	84	97	132/84
16	ABDUL HAMEED	48	M	88	98	130/80
17	MATHIALAGAN	55	M	84	96	126/80
18	PARVATHY	75	F	96	96	120/70
19	ELLAMMAL	52	F	88	98	126/80
20	PERIAYASAMY	65	M	86	98	128/78
21	SAROJA	46	F	84	98	136/78
22	ARUNA	40	F	78	97	130/80
23	RAJENDRAN	64	M	76	98	136/78
24	KRISHNAN .D	62	M	74	95	136/80
25	YETTIAPPAN	62	M	96	96	120/80
26	KANNIYAPPAN	63	M	98	96	128/88
27	MURUGAN	80	M	106	95	134/88

28	AYYAPPAN	63	M	98	98	128/80
29	GOPAL	58	M	98	95	134/78
30	SRINIVASAN	75	M	104	96	138/78
31	KUMAR	49	M	98	96	130/80
32	ARUMUGAM	67	M	98	96	120/80
33	RAJESHWARI	70	F	96	97	124/80
34	BANAKALU	72	M	88	95	124/88
35	RAYARATHINAM	73	M	96	94	120/80
36	GUNASEKAR	45	M	86	94	120/80
37	SRINIVASAN	70	M	88	97	118/84
38	SELVI	57	F	94	94	116/80
39	NALLATHAMBI	59	M	104	95	130/80
40	CHAKKARADARI	70	M	86	94	126/86
41	AYYASAMY.P	52	M	84	95	130/80
42	RADHAMMAL	75	F	86	95	126/80
43	KANNAMAL	85	F	84	94	134/78
44	AYYASAMY.S	55	M	86	94	134/76
45	VEERABATHIRAN	60	M	98	97	130/80
46	SAMUVEL	70	M	88	96	120/80
47	GANAPATHY	55	M	92	96	130/80
48	VISWANATHAN	45	M	88	95	130/80
49	VELAYUDHAM	60	M	104	98	126/80
50	KANNAN	60	M	84	96	120/80
51	GAJAPATHY	60	M	94	96	124/80
52	RAMAMOORTHY	74	M	98	95	120/80
53	SUNDARRAJ	60	M	96	96	118/80
54	MURUGESAN	67	M	88	97	130/80
55	GAJENDRAN	61	M	96	98	120/80
56	IRULANDI	67	M	88	97	130/80
57	GOPAL	72	M	78	96	126/84
58	VENUGOPAL	55	M	82	96	126/80
59	THANGAVEL	65	M	78	97	128/80
60	SATHYA	55	F	88	99	124/84
61	SENTHIL KUMAR	42	M	96	97	116/86
62	ARUNAGIRI	75	M	88	96	130/80
63	VARADHAN	55	M	94	98	120/80
64	CHINNASAMY	65	M	106	99	132/80
65	MANIMEGALAI	48	F	102	98	126/76
66	DHANDAPANI	62	M	98	97	130/80
67	LAKSHMANAN	59	M	98	98	126/84
68	AYYANAR	70	M	96	97	124/78
69	VEDHACHALAM	70	M	94	96	130/70
70	SELVAN	62	M	96	97	120/76
71	KANNIAYAPPAN	55	M	94	98	128/78

72	IYYAPAN	63	M	96	96	130/80
73	KRISHNAN	50	M	88	97	120/80
74	MURUGESAN	62	M	84	96	130/80
75	VASUDEVAN	65	M	90	96	130/80

INSTITUTIONAL ETHICAL COMMITTEE, STANLEY MEDICAL COLLEGE, CHENNAI-1

Title of the Work	:	Relationship between six minute walk test, spirometry & COPD assessment Test (CAT) Scores in Chronic Obstructive Pulmonary Disease patients.
Principal Investigator	:	Dr. P Anand
Designation	:	PG MD (TB & Respiratory Diseases)
Department	:	Department of TB & Respiratory Diseases Government Stanley Medical College, Chennai-01

The request for an approval from the Institutional Ethical Committee (IEC) was considered on the IEC meeting held on 29.09.2015 at the Council Hall, Stanley Medical College, Chennai-1 at 2PM

The members of the Committee, the secretary and the Chairman are pleased to approve the proposed work mentioned above, submitted by the principal investigator.

The Principal investigator and their team are directed to adhere to the guidelines given below:

1. You should inform the IEC in case of changes in study procedure, site investigator investigation or guide or any other changes.
2. You should not deviate from the area of the work for which you applied for ethical clearance.
3. You should inform the IEC immediately, in case of any adverse events or serious adverse reaction.
4. You should abide to the rules and regulation of the institution(s).
5. You should complete the work within the specified period and if any extension of time is required, you should apply for permission again and do the work.
6. You should submit the summary of the work to the ethical committee on completion of the work.

MEMBER SECRETARY,
IEC, SMC, CHENNAI.

MEMBER SECRETARY
ETHICAL COMMITTEE,
STANLEY MEDICAL COLLEGE
CHENNAI 600 001.

RELATIONSHIP BETWEEN SIX MINUTE WALK TEST,

SPIROMETRY AND COPD ASSESSMENT TEST (CAT) SCORES IN

CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS

Dissertation submitted In Partial Fulfilment of the

Requirements for the Degree of

DOCTOR OF MEDICINE

TUBERCULOSIS & RESPIRATORY DISEASES

Branch - XVII

2014-2017

DEPARTMENT OF TUBERCULOSIS & RESPIRATORY DISEASES